Gemcitabine activity in cervical cancer cell lines

Hernández, Patricia; Olivera, Primitivo; Dueñas‐González, Alfonso; Pérez-Pastenes, Miguel A.; Zárate, Adolfo; Maldonado, Vilma; Meléndez-Zajgla, Jorge

doi:10.1007/s002800100370

Cited by 40 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clonogenic assays were performed as reported previously. 27 The analyses were performed at least in triplicate in four independent experiments. Nuclear staining.…”

Section: Methodsmentioning

confidence: 99%

NF-κB does not influence the induction of apoptosis by Ukrain

Mendoza

Zamora²,

Gallardo³

et al. 2006

Cancer Biology & Therapy

Self Cite

View full text Add to dashboard Cite

“…Clonogenic assays were performed as reported previously. 27 The analyses were performed at least in triplicate in four independent experiments. Nuclear staining.…”

Section: Methodsmentioning

confidence: 99%

NF-κB does not influence the induction of apoptosis by Ukrain

Mendoza

Zamora²,

Gallardo³

et al. 2006

Cancer Biology & Therapy

Self Cite

View full text Add to dashboard Cite

“…Gemcitabine which is used in study arm has been shown to be a potent Radiosensitizer in cervical cell line (7) . Gemcitabine has shown promising radio sensitising effect in preclinical as well as in clinical phase II trials.…”

Section: Discussionmentioning

confidence: 99%

“…Gemcitabine is a known radiosensitizer and has been used in a wide variety of human cancer cell lines (6) . Various studies have reported that Gemcitabine is highly synergistic to radiation in cervical cancer cell lines (7) . Several trials were performed with Gemcitabine as radiosensitiser (8,9) .…”

Section: Jmscr Vol||05||issue||07||page 25734-25742||julymentioning

confidence: 99%

Feasibility of Weekly Cisplatin Versus Gemcitabine Concomitant with Radiation in The Management of Locally Advanced Carcinoma Cervix

Singh¹

2017

JMSCR

View full text Add to dashboard Cite

“…Hernandez et al 14 have demonstrated the radiosensitizing effect of gemcitabine against cervical cancer cell line. Overall toxicity was acceptable and tolerable.…”

Section: Discussionmentioning

confidence: 99%

Concurrent pelvic radiation with weekly low-dose cisplatin and gemcitabine as primary treatment of locally advanced cervical cancer: A phase II study

El-Hadaad

Wahba

Roshdy

et al. 2015

Int J Cancer Ther Oncol

View full text Add to dashboard Cite

Original ArticleAbstract Purpose: This study was done to evaluate response, compliance and survival of weekly low dose cisplatin (20 mg/m 2 ) and gemcitabine (125 mg/m 2 ) concurrently with pelvic radiation as primary treatment of stage IIB-IIIB cervical cancer. Methods: External radiation consisted of 50 Gy/25 fractions using 6-10 MV photon followed by 600 cGy boost to parametrium if it was still felt thickened. Then, intracavitary radiotherapy to deliver 60 Gy at point A. Chemotherapy consisted of gemcitabine at a dose of 125 mg /m 2 was given by i.v infusion over 30 minutes immediately after cisplatin 20 mg /m 2 weekly for 5 weeks during EBRT. Fortyfive eligible patients received the treatment protocol. Results: Toxicity was tolerable and manageable. No grade 4 toxicity while grade 3 was recorded in hematologic one only. In order of frequency; diarrhea, nausea and vomiting, and anemia (50%, 40%, 35.5%) were most common adverse events. Overall clinical response rate was 93.4% with pathological complete response of 62.2%. After median follow-up of 20 months, 2-year survival and progression-free survival rates were 90.5% and 81% respectively. Conclusion: Weekly combination of low-dose cisplatin and gemcitabine given concurrently with pelvic radiotherapy in primary treatment of locally advanced cervical cancer resulted in a high response rate with a good compliance. Further exploration is needed for the use of this approach prior to incorporating it into routine clinical care through phase III clinical trial.

show abstract

Gemcitabine activity in cervical cancer cell lines

Abstract: We recommend performing additional in vitro experimentation so that these results can be confirmed to support clinical trials of gemcitabine in cervical cancer patients both as first-line therapy and with concomitant radiation.

Cited by 40 publications

References 0 publications

NF-κB does not influence the induction of apoptosis by Ukrain

NF-κB does not influence the induction of apoptosis by Ukrain

Feasibility of Weekly Cisplatin Versus Gemcitabine Concomitant with Radiation in The Management of Locally Advanced Carcinoma Cervix

Concurrent pelvic radiation with weekly low-dose cisplatin and gemcitabine as primary treatment of locally advanced cervical cancer: A phase II study

Contact Info

Product

Resources

About